$EIKN

Eikon Therapeutics, Inc. (EIKN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001861123 false 0001861123 2026-07-31 2026-07-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31,

Baker Hughes reported Q2 earnings of 64 cents per share, which it said beat analyst consensus of 50 cents, and quarterly sales of $6.742 billion versus $6.523 billion expected. The stock rose 8.2% to $61.97 on Monday. The article also notes broad gains in U.S. equities.

Eikon Therapeutics, Inc. (EIKN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001861123 false 0001861123 2026-06-05 2026-06-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 05,

BlackRock Portfolio Management LLC has disclosed a passive investment in Eikon Therapeutics, Inc. (EIKN), holding 3,002,737 shares, which represents 5.5% of the company's common stock. This Schedule 13G filing indicates a beneficial ownership for passive purposes, with BlackRock exercising sole voting power for 2,939,120 shares and sole dispositive power for all 3,002,737 shares. The disclosure clarifies that these holdings are attributed to specific BlackRock business units and do not signify an intent to influence control over Eikon Therapeutics.